VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
BLCO
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
BLCOBausch + Lomb Corporation
$17.10$6.1B
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders

BLCO logoBausch + Lomb Corporation(BLCO)Earnings, Financials & Key Ratios

BLCO•NYSE
$17.10
Price updated Jul 7, 2026
SectorHealthcareIndustryMedical InstrumentsSub-IndustryDental and vision care devices
AboutBausch + Lomb Corporation operates as an eye health company worldwide. It operates through three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products, over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions comprising eye allergies, conjunctivitis, and dry eye. The Ophthalmic Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of eye conditions, such as glaucoma, ocular hypertension, and retinal diseases; and contact lenses for therapeutic use. The Surgical segment provides tools and technologies for the treatment of cataracts, and vitreous and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices. The company was founded in 1853 and is headquartered in Vaughan, Canada.Show more
  • Revenue$5.1B+6.5%
  • EBITDA$609M+1.8%
  • Net Income-$360M-13.6%
  • EPS (Diluted)-1.02-13.3%
  • Gross Margin54.75%-10.1%
  • EBITDA Margin11.94%-4.3%
  • Operating Margin3.69%+9.0%
  • Net Margin-7.06%-6.7%
  • ROE-5.51%-17.1%

BLCO Price & Volume

Bausch + Lomb Corporation (BLCO) stock price & volume — 10-year historical chart

Loading chart...

Persistent Margin Compression Clouds Operational Growth Trajectory

Investment Thesis • Updated 2026Q1

VerdictNegative
Growth:Decelerating
Profitability:Negative
Financial:Strained
Cash Flow:Mixed
Primary Risk:Persistent Net Margin Deficit

Key Thesis Takeaways

  • Bausch + Lomb faces a challenging path to profitability as revenue growth has decelerated from 18.0% in 2024Q1 to 9.4% by 2026Q1, compounded by persistent net losses in nine of the last ten quarters.
  • While the company maintains a current ratio of 1.53, the heavy reliance on $4.7 billion in goodwill and elevated SG&A expenses consistently absorbing gross profits suggest significant structural headwinds.
  • Investors should remain cautious until the firm demonstrates a sustainable ability to convert its $1.2 billion in quarterly revenue into positive net income and consistent free cash flow.

Verdict Logic

the company's inability to achieve consistent profitability, evidenced by a -5.7% net margin in 2026Q1, suggests that operational risks currently outweigh potential growth catalysts.

BLCO Growth Metrics

Bausch + Lomb Corporation (BLCO) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years-
5 Years8.38%
3 Years10.62%
TTM7.85%

Profit CAGR

10 Years-
5 Years-
3 Years-
TTM39.5%

EPS CAGR

10 Years-
5 Years-
3 Years-
TTM39.74%

Return on Capital

10 Years2.26%
5 Years1.91%
3 Years1.38%
Last Year1.58%

BLCO Recent Earnings

Bausch + Lomb Corporation (BLCO) EPS & revenue vs analyst estimates — last 4 quarters

Full history →
●Beat EPS 8/12 qtrs (67%)●Beat Revenue 5/12 qtrs (42%)
Q2 2026Latest
Apr 29, 2026
Metric
Actual
Est
EPS
$0.08+33.3%
$0.06
Rev
$1.2B+2.3%
$1.2B
Q1 2026
Feb 18, 2026
Metric
Actual
Est
EPS
$0.32-8.6%
$0.35
Rev
$1.4B+1.4%
$1.4B
Q4 2025
Oct 29, 2025
Metric
Actual
Est
EPS
$0.18+12.5%
$0.16
Rev
$1.3B-7.4%
$1.4B
Q3 2025
Jul 30, 2025
Metric
Actual
Est
EPS
$0.07+16.7%
$0.06
Rev
$1.3B+0.3%
$1.3B
QuarterDateEPS (Act vs Est)Revenue (Act vs Est)
Q2 2026LatestApr 29, 2026
$0.08vs $0.06+33.3%
$1.2Bvs $1.2B+2.3%
Q1 2026Feb 18, 2026
$0.32vs $0.35-8.6%
$1.4Bvs $1.4B+1.4%
Q4 2025Oct 29, 2025
$0.18vs $0.16+12.5%
$1.3Bvs $1.4B-7.4%
Q3 2025Jul 30, 2025
$0.07vs $0.06+16.7%
$1.3Bvs $1.3B+0.3%
Based on last 12 quarters of dataView full earnings history →

Latest BLCO News

Recent stock market news and headlines for Bausch + Lomb Corporation (BLCO)

Business Wire·2 days ago
Bausch + Lomb Will Release Second-Quarter 2026 Financial Results on July 29

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its second-quarter financial results on Wednesday, July 29, 2026. The company will host a conference call and live webcast at 8 a.m. ET to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch + Lomb website prior to the start of the.

Business Wire·Jul 1, 2026
New Bausch + Lomb Data Show that Addressing Dry Eye Symptoms is Associated with Improved Quality of Life, Including Lower Anxiety and Increased Self-Confidence

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced new findings from its third annual State of Dry Eye survey, which reveals that the impact of dry eye can extend beyond the burden of physical symptoms, affecting how patients view their emotional health and wellbeing. This year's survey was conducted online by The Harris Poll in May 2026 among 1,000 dry eye suff.

Peers Comparison

Key metrics vs top competitors for Bausch + Lomb Corporation (BLCO)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
BLCO logoBLCOBausch + Lomb CorporationCurrent
$17.10$6.1B-16.766.47%-7.06%-5.51%—
HSIC logoHSICHenry Schein, Inc.
$86.84$9.89B26.564.03%2.95%8.14%—
ATRC logoATRCAtriCure, Inc.
$32.80$1.66B-136.6714.88%-0.83%-0.95%—
LNTH logoLNTHLantheus Holdings, Inc.
$103.41$6.73B30.330.5%18.05%24.33%—
JNJ logoJNJJohnson & Johnson
$267.24$643.31B24.236.05%21.83%26.26%—
ABT logoABTAbbott Laboratories
$95.84$166.94B25.765.67%13.91%12.09%—

Compare BLCO vs Peers

Bausch + Lomb Corporation (BLCO) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs HSIC

Most directly comparable listed peer for BLCO.

Scale Benchmark

vs JNJ

Larger-name benchmark to compare BLCO against a more recognizable public peer.

Peer Set

Compare Top 5

vs HSIC, ATRC, LNTH, JNJ

BLCO SEC Filings & Documents

Bausch + Lomb Corporation (BLCO) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

Apr 29, 2026·SEC

Material company update

Feb 18, 2026·SEC

Material company update

Jan 2, 2026·SEC

10-K Annual Reports

3
FY 2026

Feb 18, 2026·SEC

FY 2025

Feb 19, 2025·SEC

FY 2024

Feb 21, 2024·SEC

10-Q Quarterly Reports

6
FY 2026

Apr 29, 2026·SEC

FY 2025

Oct 29, 2025·SEC

FY 2025

Jul 30, 2025·SEC

Get notified when BLCO posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

BLCO Frequently Asked Questions

Bausch + Lomb Corporation (BLCO) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
What is Bausch + Lomb Corporation's revenue?

Bausch + Lomb Corporation (BLCO) reported $5.21B in revenue for fiscal year 2025. This represents a 38% increase from $3.78B in 2019.

How fast is Bausch + Lomb Corporation growing?

Bausch + Lomb Corporation (BLCO) grew revenue by 6.5% over the past year. This is steady growth.

Is BLCO profitable?

Bausch + Lomb Corporation (BLCO) reported a net loss of $219.0M for fiscal year 2025.

Dividend & Returns
What is BLCO's return on equity?

Bausch + Lomb Corporation (BLCO) has a return on equity (ROE) of -5.5%. Negative ROE indicates the company is unprofitable.

What is Bausch + Lomb Corporation's free cash flow?

Bausch + Lomb Corporation (BLCO) generated $4.3M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

What if you invested $1,000 in BLCO back in 2019?

Total return calculator · dividends reinvested · 7+ years of data

See returns →